EODData

NASDAQ, FBRX: Forte Biosciences Inc

31 Oct 25 13:08
LAST:

12.92

CHANGE:
 0.36
OPEN:
13.27
HIGH:
13.57
ASK:
0.00
VOLUME:
7.7K
CHG(%):
2.68
PREV:
13.27
LOW:
12.75
BID:
0.00
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
31 Oct 2513.2713.5712.7512.927.7K
30 Oct 2514.3814.8913.1113.2787.3K
29 Oct 2513.6215.1013.5014.3893.6K
28 Oct 2513.1214.1813.0413.46103.9K
27 Oct 2512.2513.5112.1013.00140.0K
24 Oct 2512.1512.2511.8112.11241.5K
23 Oct 2511.6612.1511.3912.0561.1K
22 Oct 2511.6811.9411.0011.6651.4K
21 Oct 2512.3012.3011.5011.68114.2K
20 Oct 2512.0812.4610.9712.19108.0K

COMPANY PROFILE

Name:Forte Biosciences Inc
About:Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Sector:Healthcare
Industry:Biotechnology
Address:3060 Pegasus Park Drive, Dallas, TX, United States, 75247
Website:https://www.fortebiorx.com
CUSIP:34962G109
CIK:0001419041
ISIN:US34962G2084
FIGI:BBG001J2N4H0

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

TECHNICAL INDICATORS

MA5:13.454.1%
MA10:12.691.7%
MA20:13.303.0%
MA50:12.820.7%
MA100:12.116.7%
MA200:10.5023.0%
STO9:42.73
STO14:42.73
RSI14:39.23 
WPR14:-45.96
MTM14:-0.76
ROC14:-0.05 
ATR:1.20 
Week High:15.1016.9%
Week Low:11.819.4%
Month High:15.5020.0%
Month Low:10.9723.0%
Year High:28.68122.1%
Year Low:4.11214.2%
Volatility:84.82 

RECENT SPLITS

Date Ratio
28 Aug 20241-25
16 Jun 20201-15